Updates are available Correction dated 2023-02-22
Click to view Correction: https://doi.org/10.1038/s41746-023-00769-z
-
Authors
Esteva, Andre
Feng, Jean https://orcid.org/0000-0003-2041-3104
van der Wal, Douwe
Huang, Shih-Cheng
Simko, Jeffry P.
DeVries, Sandy
Chen, Emmalyn
Schaeffer, Edward M.
Morgan, Todd M. https://orcid.org/0000-0002-1140-0603
Sun, Yilun https://orcid.org/0000-0002-1341-382X
Ghorbani, Amirata
Naik, Nikhil
Nathawani, Dhruv https://orcid.org/0000-0002-0296-8408
Socher, Richard
Michalski, Jeff M.
Roach, Mack III
Pisansky, Thomas M.
Monson, Jedidiah M.
Naz, Farah
Wallace, James
Ferguson, Michelle J.
Bahary, Jean-Paul
Zou, James https://orcid.org/0000-0001-8880-4764
Lungren, Matthew
Yeung, Serena https://orcid.org/0000-0003-0529-0628
Ross, Ashley E.
,
Kucharczyk, Michael
Souhami, Luis
Ballas, Leslie
Peters, Christopher A.
Liu, Sandy
Balogh, Alexander G.
Randolph-Jackson, Pamela D.
Schwartz, David L.
Girvigian, Michael R.
Saito, Naoyuki G.
Raben, Adam
Rabinovitch, Rachel A.
Katato, Khalil
Sandler, Howard M. https://orcid.org/0000-0002-8193-5769
Tran, Phuoc T.
Spratt, Daniel E.
Pugh, Stephanie
Feng, Felix Y.
Mohamad, Osama
- License Information
-
More Information
Article History
Received: 5 January 2022
Accepted: 19 May 2022
First Online: 8 June 2022
Change Date: 22 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41746-023-00769-z
Competing interests
: A.E., D.v.d.W., and E.C. are employees at Artera. A.E., D.v.d.W., D.N., R.S., and N.N are or were employees of Salesforce.com, Inc. F.Y.F. is an advisor to and holds equity in Artera and is a consultant for Janssen, Roivant, Myovant, Bayer, Novartis, Varian, Blue Earth Diagnostics and Exact Sciences. L.S. received travel support and honorarium from Varian Medical Systems and is on the advisory board for AbbVie. M.K. received funding from Limbus AI, is a consultant for Palette Life Sciences, and is on the advisory board for AbbVie, Ferring, Janssen, and TerSera. A.E.R. is a consultant for Astellas, Bayer, Blue Earth, Janssen, Myovant, Pfizer, Progenics, and Veracyte. H.M.S. is a member of the ASTRO Board and a member of the clinical trials steering committee for Janssen. P.T.T. is a consultant for Johnson & Johnson, RefleXion Medical, Myovant, and AstraZeneca. D.E.S. is a consultant for AstraZeneca, Blue Earth, Bayer, Boston Scientific, Gammatile, Janssen, Novartis, and Varian. The remaining authors declare no competing interests.
